Biomarin Pharmaceutical Inc (MIL:1BMRN)
€ 70.52 0 (0%) Market Cap: 13.26 Bil Enterprise Value: 13.31 Bil PE Ratio: 70.58 PB Ratio: 2.82 GF Score: 62/100

Biomarin Pharmaceutical Inc at Stifel Healthcare Conference (Virtual) Transcript

Nov 17, 2021 / 04:20PM GMT
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

Awesome. Thanks very much. It's my pleasure to be hosting the BioMarin management team here. We have Hank Fuchs and Brian Mueller. Good to see you guys. Thanks for taking the time away from I'm sure what is probably a busy week for you. Hank, do you want to kick things off and just sort of give a quick update on the company and then I can chime away.

Henry J. Fuchs
BioMarin Pharmaceutical Inc. - President of Worldwide Research & Development

Thanks, Paul. Brian and I appreciate the opportunity to join you today, and we're just a few weeks remaining in '21. We look forward to '22 with great excitement. As the head of R&D, I'm very pleased with the execution of our pipeline pivot from ultra-rare products to products that address more prevalently affected genetic conditions.

Our mission to translate genetic discoveries and the transformative medicines has not changed but the ability to leverage our deep

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot